EFFECTS OF LONG-TERM ROUX-EN-Y GASTRIC BYPASS ON BODY WEIGHT AND CLINICAL METABOLIC COMORBIDITIES IN BARIATRIC SURGERY SERVICE OF A UNIVERSITY HOSPITAL.
Due to the high failure rate observed in the clinical treatment of morbid obesity an increase in bariatric surgery indications, as an alternative for the control of obesity and comorbidities, is noticeable.



To evaluate the performance of type 2 diabetes mellitus, high blood pressure and dyslipidemia in patients submitted to Roux-en-Y gastric bypass in late follow-up.



Retrospective analysis of 59 patients included in the bariatric surgery program. Anthropometric (height and body weight) and laboratory (LDLc, HDLc, VLDLc, triglyceride -TG - and glucose) data were collected on pre- and postoperative stages, through medical records.



Among the patients, 86% were female aged 43±11, of whom 52% had attended high school. The average postoperative time was 7±3 years. During the postoperative period, there were decreases of weight and body mass index, respectively (133±06 kg vs 91±04 kg p<0.05 e 49±74 kg/m2 vs 33±79 kg/m2, p<0.05). In comparison to the preoperative stage, lower concentrations of glucose (101.00±26.99 vs 89,11±15.19, p=0.014), total cholesterol rates (179.00±37,95 vs 167.48±28,50, p=0.016), LDLc (104.30±33.12 vs 91.46±24.58, p=0.016), VLDLc (25.40±11,12 vs 15.68±7.40, p<0.01), and TG (143.35±86.35 vs 82.45±37.39, p<0.01) and higher concentrations of HDLc (43.53±8.23 vs 57.90±15.60, p<0.01) were identified in the postoperative stage. 40% of hypertensive patients were still undergoing high blood pressure treatment during the postoperative stage. There was remission of type 2 diabetes mellitus and dyslipidemia on 81% and 94% of the cases, respectively.



Roux-en-Y gastric bypass has proven itself to be an effective long term procedure, promoting weight loss, remission of DM2 and dyslipidemia.
Bariatric Surgery Program, Clementino Fraga Filho Hospital, Federal University of Rio de Janeiro.|Josué de Castro Nutrition Institute, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
Cátia Ferreira da
CF
Silva
Bariatric Surgery Program, Clementino Fraga Filho Hospital, Federal University of Rio de Janeiro.
Larissa
L
Cohen
Bariatric Surgery Program, Clementino Fraga Filho Hospital, Federal University of Rio de Janeiro.
Luciana d'Abreu
LD
Sarmento
Bariatric Surgery Program, Clementino Fraga Filho Hospital, Federal University of Rio de Janeiro.
Felipe Monnerat Marino
FM
Rosa
Josué de Castro Nutrition Institute, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
Eliane Lopes
EL
Rosado
Bariatric Surgery Program, Clementino Fraga Filho Hospital, Federal University of Rio de Janeiro.
João Régis Ivar
JR
Carneiro
Bariatric Surgery Program, Clementino Fraga Filho Hospital, Federal University of Rio de Janeiro.
Antônio Augusto Peixoto de
AA
Souza
Bariatric Surgery Program, Clementino Fraga Filho Hospital, Federal University of Rio de Janeiro.|Josué de Castro Nutrition Institute, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
Fernanda Cristina Carvalho Mattos
FC
Magno
Arq Bras Cir Dig. 2014 Jan-Mar;27(1):38-42
24676297
Arq Bras Cir Dig. 2015 Nov-Dec;28(4):270-3
26734799
Arq Bras Cir Dig. 2015;28 Suppl 1:15-8
26537266
Endocrinology. 2009 Jun;150(6):2518-25
19372197
Obes Surg. 2003 Apr;13(2):159-60
12760387
Diabetologia. 2012 Jul;55(7):1890-901
22538359
Diabetes Metab J. 2014 Dec;38(6):406-15
25541603
Arq Bras Cir Dig. 2015;28 Suppl 1:26-30
26537269
JAMA. 2004 Oct 13;292(14):1724-37
15479938
Surg Obes Relat Dis. 2011 Jul-Aug;7(4):473-9
21036105
Int J Obes Relat Metab Disord. 2002 Nov;26(11):1434-41
12439644
Am J Hum Biol. 2003 Nov-Dec;15(6):824-34
14595874
World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253
11234459
Rev Saude Publica. 2009 Nov;43 Suppl 2:83-9
19936502
J Clin Endocrinol Metab. 2008 Jul;93(7):2479-85
18430778
J Clin Endocrinol Metab. 2004 Jun;89(6):2608-15
15181031
Obes Res. 2004 Mar;12(3):369-439
15044658
Arq Bras Cardiol. 2010 Jul;95(1 Suppl):1-51
21085756